Sanford C. Bernstein set a €88.00 ($102.33) target price on Bayer (FRA:BAYN) in a report released on Wednesday. The brokerage currently has a buy rating on the healthcare company’s stock.

Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on shares of Bayer and gave the company a buy rating in a research report on Monday, August 13th. Commerzbank set a €111.00 ($129.07) price objective on shares of Bayer and gave the company a buy rating in a research report on Monday, August 13th. Barclays set a €110.00 ($127.91) price objective on shares of Bayer and gave the company a buy rating in a research report on Monday, August 13th. Goldman Sachs Group set a €116.00 ($134.88) price objective on shares of Bayer and gave the company a buy rating in a research report on Monday, August 13th. Finally, Cfra set a €100.00 ($116.28) price objective on shares of Bayer and gave the company a buy rating in a research report on Tuesday, August 14th. Six research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of €90.80 ($105.58).

Shares of BAYN opened at €63.43 ($73.76) on Wednesday. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: Stop Order

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.